I'm happy to do that.
For Genome, as the deputy indicates, the reduction in funding is about cashflow and it's off a much larger base. It's not off the $22 million. It's off the $86 million.
They continue to be operating large-scale contribution programs in multiple areas of genomic science. I think we tend to think about genomics as very specifically in the issues of human health, but there are obviously genomics applications in a wide variety of sectors, including such areas as agriculture, mining, and promoting environmental sustainability. One thing Genome seeks to do is to have competitions and fund research in a variety of sectors. They work with regional genomic centres across the country that can be focusing on various kinds of specific needs in specific economic sectors.
Again, it could appear that this is a move from $22 million to $7 million, a much larger decrease than it actually is. This is really more about their current cashflow needs.